Previous 10 | Next 10 |
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Tuesday, August 2, 2022. Company managemen...
FDA approved technology to treat severe emphysema. Sizeable $12 billion market opportunity. Continue to struggle with adoption due to COVID-19 disruptions. Richly valued relative to peers and growth rate. The best thing to do during an equity bear market is to not gi...
The following slide deck was published by Pulmonx Corporation in conjunction with this event. For further details see: Pulmonx (LUNG) Investor Presentation - Slideshow
Pulmonx Corporation (LUNG) Q1 2022 Results Earnings Conference Call May 03, 2022, 04:30 PM ET Company Participants Brian Johnston - VP, Investor Relations, Gilmartin Group Glendon French - President & Chief Executive Officer Derrick Sung - Chief Financial Officer Conference Call Participa...
Image source: The Motley Fool. Pulmonx Corporation (NASDAQ: LUNG) Q1 2022 Earnings Call May 03, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Pulmonx Corporation (LUNG) Q1 2022 Earnings Call Transcript
Pulmonx press release (NASDAQ:LUNG): Q1 GAAP EPS of -$0.43 misses by $0.06. Revenue of $10.8M (+17.4% Y/Y) beats by $1.54M. Expect revenue for the full year 2022 to be in the range of $55 million to $60 million. For further details see: Pulmonx GAAP EPS of -$0.43 misses by $0.06, revenu...
REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter ended March 31, 2022. Recen...
REDWOOD CITY, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Bank of America Securities 2022 Healthcare...
REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2022 after the close of t...
The following slide deck was published by Pulmonx Corporation in conjunction with their 2021 Q4 earnings call. For further details see: Pulmonx Corporation 2021 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading...
2024-06-23 01:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...